Suppliers / Emnar Pharma

Emnar Pharma

India Updated 9 July 2026

Emnar Pharma is an API manufacturer based in India. It holds 56 active US drug master files and 6 valid CEPs across a filed portfolio of 26 molecules. Its filings concentrate with CDSCO (India) and MINSA (CR). Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 28 August 2025 as VAI. Customs aggregates show $3.0M of exports covering 72 molecules to 22 destinations in 2025.

56
active US DMFs
6
valid CEPs
2
registered plants 1 with an FDA FEI number
2
filings across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 28 August 2025 VAI US FDA
  • 6 June 2019 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Anakapalli (District), India 3012336575
Hyderabad, India Not on file

What they file, and where

Molecule Regulators Docs
Sodium Bicarbonate EDQM, US FDA 5
Empagliflozin US FDA 4
Lacosamide EDQM, US FDA 3
Levetiracetam EDQM, US FDA 3
Lithium Carbonate EDQM, US FDA 3
Potassium EDQM, US FDA 3
Tramadol EDQM, US FDA 3
Acotiamide US FDA 2
Apixaban US FDA 2
Bupropion US FDA 2
Show all 26 molecules on file
Calcium Carbonate US FDA 2
Capecitabine US FDA 2
Copper US FDA 2
Dapagliflozin US FDA 2
Dolutegravir US FDA 2
Gabapentin US FDA 2
Lamivudine US FDA 2
Linezolid US FDA 2
Magnesium US FDA 2
Pitolisant US FDA 2
Potassium Chloride US FDA 2
Potassium Sulfate US FDA 2
Pridinol US FDA 2
Tenofovir Disoproxil US FDA 2
Valproic Acid US FDA 2
Zonisamide US FDA 2

Also appears on these molecule pages

Bupropion API Calcium Carbonate API Capecitabine API Dolutegravir API Gabapentin API Lacosamide API Lamivudine API Levetiracetam API Linezolid API Lithium Carbonate API Pitolisant API Tenofovir Disoproxil API
Show 6 more molecule pages
Tramadol API Valproic Acid API Zonisamide API Empagliflozin API Dapagliflozin API Apixaban API

Filings and GMP by regulator

Regulator Filings GMP certificates
CDSCO (India) 1 None
MINSA (CR) 1 None
US FDA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $772K 8
2025 Not reported $3.0M 22
2024 Not reported $2.9M 27
2023 Not reported $91K 5

Export figures are customs aggregates. We do not publish the identity of any buyer.

Questions about Emnar Pharma

Does Emnar Pharma hold a US DMF or a CEP?
Emnar Pharma holds 56 active US drug master files and 6 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Emnar Pharma FDA-registered?
One site operated by Emnar Pharma carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Emnar Pharma's last inspection go?
The most recent inspection on record closed on 28 August 2025 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 2 inspections are on file.
Where does Emnar Pharma manufacture?
2 registered sites are on record, in India (Anakapalli (district) and Hyderabad). Every site is listed on this page with the register it came from.
What does Emnar Pharma make?
26 molecules are on record against Emnar Pharma, including Sodium Bicarbonate, Empagliflozin, Lacosamide and Levetiracetam. Each links through to that molecule's full manufacturer list.
Which regulators recognise Emnar Pharma's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Emnar Pharma comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 28 August 2025.

Comparable suppliers

Hetero shares 9 molecules Apitoria Pharma shares 7 molecules Alivus Life Sciences shares 5 molecules Zydus Lifesciences shares 5 molecules Macleods Pharmaceuticals shares 5 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts